Table of Contents Author Guidelines Submit a Manuscript
Journal of Oncology
Volume 2010 (2010), Article ID 568938, 20 pages
http://dx.doi.org/10.1155/2010/568938
Review Article

Targeting the Epidermal Growth Factor Receptor in Epithelial Ovarian Cancer: Current Knowledge and Future Challenges

1Department of Systems Biology, The University of Texas M. D. Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA
2Department of Gynecologic Medical Oncology, The University of Texas M. D. Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA

Received 1 May 2009; Accepted 31 August 2009

Academic Editor: Maurie M. Markman

Copyright © 2010 Doris R. Siwak et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Citations to this Article [57 citations]

The following is the list of published articles that have cited the current article.

  • Yisheng Jiao, Wenbin Ou, Fanguo Meng, Haimeng Zhou, and Aiyuan Wang, “Targeting HSP90 in ovarian cancers with multiple receptor tyrosine kinase coactivation,” Molecular Cancer, vol. 10, 2011. View at Publisher · View at Google Scholar
  • Aurelia Noske, Michael Schwabe, Wilko Weichert, Silvia Darb-Esfahani, Ann-Christin Buckendahl, Jalid Sehouli, Elena I. Braicu, Jan Budczies, Manfred Dietel, and Carsten Denkert, “An intracellular targeted antibody detects EGFR as an independent prognostic factor in ovarian carcinomas,” Bmc Cancer, vol. 11, 2011. View at Publisher · View at Google Scholar
  • Maria V. Barbolina, Rebecca J. Burkhalter, and M. Sharon Stack, “Diverse mechanisms for activation of Wnt signalling in the ovarian tumour microenvironment,” Biochemical Journal, vol. 437, no. 1, pp. 1–12, 2011. View at Publisher · View at Google Scholar
  • Q. Sheng, and J. Liu, “The therapeutic potential of targeting the EGFR family in epithelial ovarian cancer,” British Journal Of Cancer, vol. 104, no. 8, pp. 1241–1245, 2011. View at Publisher · View at Google Scholar
  • Michael Wittinger, Petr Vanhara, Ahmed El-Gazzar, Bettina Savarese-Brenner, Dietmar Pils, Mariam Anees, Thomas W. Grunt, Maria Sibilia, Martin Holcmann, Reinhard Horvat, Michael Schemper, Robert Zeillinger, Christian Schoefer, Helmut Dolznig, Peter Horak, and Michael Krainer, “hVps37A Status Affects Prognosis and Cetuximab Sensitivity in Ovarian Cancer,” Clinical Cancer Research, vol. 17, no. 24, pp. 7816–7827, 2011. View at Publisher · View at Google Scholar
  • C Alberti, P Pinciroli, B Valeri, R Ferri, A Ditto, K Umezawa, M Sensi, S Canevari, and A Tomassetti, “Ligand-dependent EGFR activation induces the co-expression of IL-6 and PAI-1 via the NFkB pathway in advanced-stage epithelial ovarian cancer,” Oncogene, vol. 31, no. 37, pp. 4139–4149, 2011. View at Publisher · View at Google Scholar
  • Sonia Dutta, Feng-qiang Wang, Hai-shan Wu, Thayer J. Mukherjee, and David A. Fishman, “The NF-kappa B pathway mediates lysophosphatidic acid (LPA)-induced VEGF signaling and cell invasion in epithelial ovarian cancer (EOC),” Gynecologic Oncology, vol. 123, no. 1, pp. 129–137, 2011. View at Publisher · View at Google Scholar
  • Johanne I. Weberpals, Madhuri Koti, and Jeremy A. Squire, “Targeting genetic and epigenetic alterations in the treatment of serous ovarian cancer,” Cancer Genetics, vol. 204, no. 10, pp. 525–535, 2011. View at Publisher · View at Google Scholar
  • Xiaomei Liu, Aiyuan Wang, Hong Gao, Zhengwei Yuan, and Yisheng Jiao, “Expression and role of the inhibitor of apoptosis protein livin in chemotherapy sensitivity of ovarian carcinoma,” International Journal Of Oncology, vol. 41, no. 3, pp. 1021–1028, 2012. View at Publisher · View at Google Scholar
  • Behrouz Zand, Robert L. Coleman, and Anil K. Sood, “Targeting Angiogenesis in Gynecologic Cancers,” Hematology-Oncology Clinics of North America, vol. 26, no. 3, pp. 543–+, 2012. View at Publisher · View at Google Scholar
  • A. H. Daneshmanesh, M. Hojjat-Farsangi, A. S. Khan, M. Jeddi-Tehrani, M. M. Akhondi, A. A. Bayat, R. Ghods, A-R Mahmoudi, R. Hadavi, A. Osterborg, F. Shokri, H. Rabbani, and H. Mellstedt, “Monoclonal antibodies against ROR1 induce apoptosis of chronic lymphocytic leukemia (CLL) cells,” Leukemia, vol. 26, no. 6, pp. 1348–1355, 2012. View at Publisher · View at Google Scholar
  • Jason A. Wilken, Tayf Badri, Sarah Cross, Rhoda Raji, Alessandro D. Santin, Peter Schwartz, Adam J. Branscum, Andre T. Baron, Adam I. Sakhitab, and Nita J. Maihle, “EGFR/HER-targeted therapeutics in ovarian cancer,” Future Medicinal Chemistry, vol. 4, no. 4, pp. 447–469, 2012. View at Publisher · View at Google Scholar
  • Parthasarathy Seshacharyulu, Moorthy P. Ponnusamy, Dhanya Haridas, Maneesh Jain, Apar K. Ganti, and Surinder K. Batra, “Targeting the EGFR signaling pathway in cancer therapy,” Expert Opinion on Therapeutic Targets, vol. 16, no. 1, pp. 15–31, 2012. View at Publisher · View at Google Scholar
  • Donavon Hiss, “Optimizing Molecular-Targeted Therapies in Ovarian Cancer: The Renewed Surge of Interest in Ovarian Cancer Biomarkers and Cell Signaling Pathways,” Journal of Oncology, vol. 2012, pp. 1–23, 2012. View at Publisher · View at Google Scholar
  • Lei Zhu, Lin Zhao, Meizhi Wu, Zhange Chen, and Huangjin Li, “B-Cell Epitope Peptide Vaccination Targeting Dimer Interface of Epidermal Growth Factor Receptor (EGFR),” Immunology Letters, 2013. View at Publisher · View at Google Scholar
  • N Panupinthu, S Yu, D Zhang, F Zhang, M Gagea, Y Lu, J R Grandis, S E Dunn, H Y Lee, and G B Mills, “Self-reinforcing loop of amphiregulin and Y-box binding protein-1 contributes to poor outcomes in ovarian cancer,” Oncogene, 2013. View at Publisher · View at Google Scholar
  • Yakup Kumtepe, Zekai Halici, Ozlem Sengul, Celalettin Semih Kunak, Yasin Bayir, Nergiz Kilic, Elif Cadirci, Alparslan Pulur, and Zafer Bayraktutan, “High serum HTATIP2/TIP30 level in serous ovarian cancer as prognostic or diagnostic marker.,” European journal of medical research, vol. 18, pp. 18, 2013. View at Publisher · View at Google Scholar
  • Umberto Leone Roberti Maggiore, Filippo Bellati, Ilary Ruscito, Maria Luisa Gasparri, Franco Alessandri, Pier Luigi Venturini, and Simone Ferrero, “Monoclonal antibodies therapies for ovarian cancer,” Expert Opinion on Biological Therapy, vol. 13, no. 5, pp. 739–764, 2013. View at Publisher · View at Google Scholar
  • Jung-Chien Cheng, Xin Qiu, Hsun-Ming Chang, and Peter C.K. Leung, “HER2 mediates epidermal growth factor-induced down-regulation of E-cadherin in human ovarian cancer cells,” Biochemical and Biophysical Research Communications, vol. 434, no. 1, pp. 81–86, 2013. View at Publisher · View at Google Scholar
  • Yu-Ming Yeh, Chi-Mu Chuang, Kuan-Chong Chao, and Lu-Hai Wang, “MicroRNA-138 suppresses ovarian cancer cell invasion and metastasis by targeting SOX4 and HIF-1α,” International Journal of Cancer, 2013. View at Publisher · View at Google Scholar
  • Susana Banerjee, and Stanley B. Kaye, “New Strategies in the Treatment of Ovarian Cancer: Current Clinical Perspectives and Future Potential,” Clinical Cancer Research, vol. 19, no. 5, pp. 961–968, 2013. View at Publisher · View at Google Scholar
  • Long Nguyen, Segundo Joel Cardenas-Goicoechea, Pierre Gordon, Christina Curtin, Mazdak Momeni, Linus Chuang, and David Fishman, “Biomarkers for early detection of ovarian cancer,” Women's Health, vol. 9, no. 2, pp. 171–187, 2013. View at Publisher · View at Google Scholar
  • Mark A. Marzinke, Caitlin H. Choi, Li Chen, Ie-Ming Shih, Daniel W. Chan, and Hui Zhang, “Proteomic Analysis of Temporally Stimulated Ovarian Cancer Cells for Biomarker Discovery,” Molecular & Cellular Proteomics, vol. 12, no. 2, pp. 356–368, 2013. View at Publisher · View at Google Scholar
  • J. Lopez, S. Banerjee, and S. B. Kaye, “New developments in the treatment of ovarian cancer--future perspectives,” Annals of Oncology, vol. 24, no. suppl10, pp. x69–x76, 2013. View at Publisher · View at Google Scholar
  • Karthik M. Kodigepalli, Punashi S. Dutta, Kyle A. Bauckman, and Meera Nanjundan, “SnoN/SkiL expression is modulated via arsenic trioxide-induced activation of the PI3K/AKT pathway in ovarian cancer cells,” FEBS Letters, vol. 587, no. 1, pp. 5–16, 2013. View at Publisher · View at Google Scholar
  • Laurie Elit, and Hal Hirte, “Palliative systemic therapy for women with recurrent epithelial ovarian cancer: current options,” Oncotargets And Therapy, vol. 6, 2013. View at Publisher · View at Google Scholar
  • Ana C. Parente-Pereira, Lynsey M. Whilding, Sjoukje J. C. van der Stegen, David M. Davies, Nancy Brewig, Scott Wilkie, Sadaf Ghaem-Maghami, May C. I. van Schalkwyk, and John Maher, “Synergistic Chemoimmunotherapy of Epithelial Ovarian Cancer Using ErbB-Retargeted T Cells Combined with Carboplatin,” Journal Of Immunology, vol. 191, no. 5, pp. 2437–2445, 2013. View at Publisher · View at Google Scholar
  • May Cho, Syeda M. Kabir, Yuanlin Dong, Eunsook Lee, Valerie Montgomery Rice, Dineo Khabele, and Deok-Soo Son, “Aspirin Blocks EGF-stimulated Cell Viability in a COX-1 Dependent Manner in Ovarian Cancer Cells,” Journal of Cancer, vol. 4, no. 8, pp. 671–678, 2013. View at Publisher · View at Google Scholar
  • Erica A. Golemis, Samuel Litwin, Hanqing Liu, Fang Xiao, Shane W. O'Brien, David A. Proia, Ilya G. Serebriiskii, Igor Astsaturov, Denise C. Connolly, Marisa A. Maglaty, and Lainie P. Martin, “Network Analysis Identifies an HSP90-Central Hub Susceptible in Ovarian Cancer,” Clinical Cancer Research, vol. 19, no. 18, pp. 5053–5067, 2013. View at Publisher · View at Google Scholar
  • Deok-Soo Son, Yuanlin Dong, Samuel E. Adunyah, Syeda M. Kabir, and Eunsook Lee, “Characteristics of chemokine signatures elicited by EGF and TNF in ovarian cancer cells,” Journal Of Inflammation-London, vol. 10, 2013. View at Publisher · View at Google Scholar
  • B T Paul, Z Blanchard, M Ridgway, and W M ElShamy, “BRCA1-IRIS inactivation sensitizes ovarian tumors to cisplatin,” Oncogene, 2014. View at Publisher · View at Google Scholar
  • Xin Qiu, Jung-Chien Cheng, Hsun-Ming Chang, and Peter C. K. Leung, “COX2 and PGE2 mediate EGF-induced E-cadherin-independent human ovarian cancer cell invasion,” Endocrine-Related Cancer, vol. 21, no. 4, pp. 533–543, 2014. View at Publisher · View at Google Scholar
  • Eleonora Teplinsky, Stephanie Blank, and Franco Muggia, “Epidermal growth factor receptor: will it ever become a therapeutic target in ovarian cancer?,” Translational Cancer Research, vol. 3, no. 2, pp. 119–123, 2014. View at Publisher · View at Google Scholar
  • Dineo Khabele, Syeda M. Kabir, Yuanlin Dong, Eunsook Lee, Valerie Montgomery Rice, and Deok-Soo Son, “Preferential Effect of Akt2-Dependent Signaling on the Cellular Viability of Ovarian Cancer Cells in Response to EGF,” Journal of Cancer, vol. 5, no. 8, pp. 670–678, 2014. View at Publisher · View at Google Scholar
  • Michaela L. Granados, Laurie G. Hudson, and Sabrina L. Samudio-Ruiz, “Contributions of the Epidermal Growth Factor Receptor to Acquisition of Platinum Resistance in Ovarian Cancer Cells,” Plos One, vol. 10, no. 9, 2015. View at Publisher · View at Google Scholar
  • Eirik Sundby, Jin Han, Svein Jacob Kaspersen, and Bård Helge Hoff, “In vitro baselining of new pyrrolopyrimidine EGFR-TK inhibitors with Erlotinib,” European Journal of Pharmaceutical Sciences, 2015. View at Publisher · View at Google Scholar
  • Wei Wen, Jun Wu, Lucy Liu, Yan Tian, Ralf Buettner, Meng-Yin Hsieh, David Horne, Thanh H Dellinger, Ernest S Han, Richard Jove, and John H Yim, “Synergistic anti-tumor effect of combined inhibition of EGFR and JAK/STAT3 pathways in human ovarian cancer,” Molecular Cancer, vol. 14, no. 1, 2015. View at Publisher · View at Google Scholar
  • S Carvalho, M Lindzen, M Lauriola, N Shirazi, S Sinha, A Abdul-Hai, K Levanon, J Korach, I Barshack, Y Cohen, A Onn, G Mills, and Y Yarden, “An antibody to amphiregulin, an abundant growth factor in patients’ fluids, inhibits ovarian tumors,” Oncogene, 2015. View at Publisher · View at Google Scholar
  • Anil Belur Nagaraj, Peronne Joseph, and Analisa DiFeo, “miRNAs as prognostic and therapeutic tools in epithelial ovarian cancer,” Biomarkers in Medicine, vol. 9, no. 3, pp. 241–257, 2015. View at Publisher · View at Google Scholar
  • Majid Momeny, Reza Ghasemi, Giovanni Valenti, Mariska Miranda, Ali Zekri, Ghazaleh Zarrinrad, Sepehr Javadikooshesh, Marjan Yaghmaie, Kamran Alimoghaddam, Ardeshir Ghavamzadeh, and Seyed H. Ghaffari, “Effects of silibinin on growth and invasive properties of human ovarian carcinoma cells through suppression of heregulin/HER3 pathway,” Tumor Biology, 2015. View at Publisher · View at Google Scholar
  • Christine Mehner, Ellen L. Goode, Gary L. Keeney, Aminah Jatoi, Miklós Sahin-Tóth, John A. Copland, Derek C. Radisky, Evette S. Radisky, Ann L. Oberg, Kimberly R. Kalli, Aziza Nassar, Alexandra Hockla, Devon Pendlebury, Magdalena A. Cichon, Krista M. Goergen, and Matthew J. Maurer, “Serine protease inhibitor Kazal type 1 (SPINK1) drives proliferation and anoikis resistance in a subset of ovarian cancers,” Oncotarget, vol. 6, no. 34, pp. 35737–35754, 2015. View at Publisher · View at Google Scholar
  • Jin Han, Silje Henriksen, Kristin G. Nørsett, Eirik Sundby, and Bård Helge Hoff, “Balancing potency, metabolic stability and permeability in pyrrolopyrimidine-based EGFR inhibitors,” European Journal of Medicinal Chemistry, 2016. View at Publisher · View at Google Scholar
  • Wei-Lin Huang, Zhongyou Li, Ting-Yu Lin, Sheng-Wen Wang, Fang-Ju Wu, and Ching-Wei Luo, “Thyrostimulin-TSHR signaling promotes the proliferation of NIH:OVCAR-3 ovarian cancer cells via trans-regulation of the EGFR pathway,” Scientific Reports, vol. 6, pp. 27471, 2016. View at Publisher · View at Google Scholar
  • Jin Han, Svein Jacob Kaspersen, Sondre Nervik, Kristin Nørsett, Eirik Sundby, and Bård Helge Hoff, “Chiral 6-aryl-furo[2,3-d]pyrimidin-4-amines as EGFR inhibitors,” European Journal of Medicinal Chemistry, 2016. View at Publisher · View at Google Scholar
  • Kimberly R. Kanigel Winner, Mara P. Steinkamp, Rebecca J. Lee, Maciej Swat, Carolyn Y. Muller, Melanie E. Moses, Yi Jiang, and Bridget S. Wilson, “Spatial Modeling of Drug Delivery Routes for Treatment of Disseminated Ovarian Cancer,” Cancer Research, vol. 76, no. 6, pp. 1320–1334, 2016. View at Publisher · View at Google Scholar
  • Rania Showeil, Rachael Natrajan, Letizia Foroni, Richard Osborne, Mona El-Bahrawy, Claudia Romano, Mikel Valganon, Maryou Lambros, Pritesh Trivedi, Susan Van Noorden, Ruethairat Sriraksa, Dalal El-Kaffash, and Nour El-Etreby, “The status of epidermal growth factor receptor in borderline ovarian tumours.,” Oncotarget, vol. 7, no. 9, pp. 10568–77, 2016. View at Publisher · View at Google Scholar
  • Jennifer McLachlan, Joao Paulo da Silveira Nogueira Lima, Lucy Dumas, and Susana Banerjee, “Targeted agents and combinations in ovarian cancer: where are we now?,” Expert Review of Anticancer Therapy, vol. 16, no. 4, pp. 441–454, 2016. View at Publisher · View at Google Scholar
  • Rosa Mistica C. Ignacio, Syeda M. Kabir, Eun-Sook Lee, Samuel E. Adunyah, and Deok-Soo Son, “NF-κB-Mediated CCL20 Reigns Dominantly in CXCR2-Driven Ovarian Cancer Progression,” Plos One, vol. 11, no. 10, pp. e0164189, 2016. View at Publisher · View at Google Scholar
  • Jung-Chien Cheng, Hsun-Ming Chang, Siyuan Xiong, Wai-Kin So, and Peter C.K. Leung, “Sprouty2 inhibits amphiregulin-induced down-regulation of E-cadherin and cell invasion in human ovarian cancer cells,” Oncotarget, vol. 7, no. 49, pp. 81645–81660, 2016. View at Publisher · View at Google Scholar
  • Ke Wang, Dan Li, and Lu Sun, “High levels of EGFR expression in tumor stroma are associated with aggressive clinical features in epithelial ovarian cancer,” Oncotargets And Therapy, vol. 9, pp. 377–386, 2016. View at Publisher · View at Google Scholar
  • Tzu-Chi Lin, Syue-Ting Chen, Min-Chuan Huang, John Huang, Chia-Lang Hsu, Hsueh-Fen Juan, Ho-Hsiung Lin, and Chi-Hau Chen, “GALNT6 expression enhances aggressive phenotypes of ovarian cancer cells by regulating EGFR activity.,” Oncotarget, vol. 8, no. 26, pp. 42588–42601, 2017. View at Publisher · View at Google Scholar
  • Majid Momeny, Ghazaleh Zarrinrad, Farima Moghaddaskho, Arash Poursheikhani, Ghazaleh Sankanian, Azam Zaghal, Shahab Mirshahvaladi, Fatemeh Esmaeili, Haniyeh Eyvani, Farinaz Barghi, Zahra Sabourinejad, Zivar Alishahi, Hassan Yousefi, Reza Ghasemi, Leila Dardaei, Davood Bashash, Bahram Chahardouli, Ahmad R. Dehpour, Javad Tavakkoly-Bazzaz, Kamran Alimoghaddam, Ardeshir Ghavamzadeh, and Seyed H. Ghaffari, “Dacomitinib, a pan-inhibitor of ErbB receptors, suppresses growth and invasive capacity of chemoresistant ovarian carcinoma cells,” Scientific Reports, vol. 7, no. 1, 2017. View at Publisher · View at Google Scholar
  • Christine Mehner, Derek C Radisky, Evette S Radisky, Ann L Oberg, Krista M Goergen, Kimberly R Kalli, Matthew J Maurer, Aziza Nassar, Ellen L Goode, Gary L Keeney, and Aminah Jatoi, “EGFR as a prognostic biomarker and therapeutic target in ovarian cancer: evaluation of patient cohort and literature review.,” Genes & cancer, vol. 8, no. 5-6, pp. 589–599, 2017. View at Publisher · View at Google Scholar
  • Kuo-Chang Wen, Pi-Lin Sung, Shie-Liang Hsieh, Yu-Ting Chou, Oscar Kuang-Sheng Lee, Cheng-Wen Wu, and Peng-Hui Wang, “α2,3-sialyltransferase type I regulates migration and peritoneal dissemination of ovarian cancer cells.,” Oncotarget, vol. 8, no. 17, pp. 29013–29027, 2017. View at Publisher · View at Google Scholar
  • Najmeh Rahmanian, Seyed Jalal Hosseinimehr, Ali Khalaj, Zohreh Noaparast, Seyed Mohammad Abedi, and Omid Sabzevari, “99mTc labeled HYNIC-EDDA/tricine-GE11 peptide as a successful tumor targeting agent,” Medicinal Chemistry Research, 2017. View at Publisher · View at Google Scholar
  • Jingying Zheng, Lijing Zhao, Yi Wang, Shuhua Zhao, and Manhua Cui, “Clinicopathology of EpCAM and EGFR in Human Epithelial Ovarian Carcinoma.,” Open medicine (Warsaw, Poland), vol. 12, pp. 39–44, 2017. View at Publisher · View at Google Scholar
  • Kevin Brasseur, Nicolas Gévry, and Eric Asselin, “Chemoresistance and targeted therapies in ovarian and endometrial cancers.,” Oncotarget, vol. 8, no. 3, pp. 4008–4042, 2017. View at Publisher · View at Google Scholar